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1. Introduction 
Nitric oxide – a free radical molecule – has been known for many decades, but only since its 
recognition as endothelium-derived relaxing factor (EDRF) the interest in the molecule has 
exponentially increased (Moncada, 1991). At the present time NO is an important messenger 
that regulates numerous functions and also participates in the pathogenesis of various diseases 
(Lloyd-Jones & Block, 1996). NO is generated from the conversion of arginine to citrulline in a 
multistep oxidation process by the NO-synthase (NOS), a NADPH-dependent enzyme that 
requires Calcium-Calmodulin, Flavinadeninedinucleotide, Flavinmononcleotide and 
Tetrahydro-L-biopterin as cofactors (Förstermann et al., 1994). Three isoforms of NOS have 
been identified. All isoenzymes, the neuronal NOS (nNOS), the inducible NOS (iNOS) and the 
endothelial NOS (eNOS) (Liu & Huang, 2008), are homodimers with subunits of 130 – 160 
kDa. As major signalling molecule of the vascular system NO is generated by the 
constitutively expressed eNOS. 
2. Endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) function 
2.1 eNOS  
The endothelium maintains the balance between vasodilation and vasoconstriction. NO 
generated by eNOS acts via cGMP-dependent pathway in a paracrine manner on 
neighbouring smooth muscle cells (SMC) diffusing radially from the production site. NO 
has a half-life of only a few milliseconds in vivo (Tab. 1) and rapidly reacts with iron of the 
heme moiety in the active site of the enzyme guanylate cyclase, stimulating it to produce the 
intracellular cGMP that in turn enhances the release of neurotransmitters resulting in SMC 
relaxation and vasodilation (Fig. 1). Acting via cGMP-independent pathways it is used in 
part to S-nitrosylation of intracellular or extracellular proteins (Castel & Vaudry, 2001; 
Mallis et al., 2001; Sun et al., 2001) or by inhibiting intraendothelial generated superoxide 
anions (Clancy et al., 1992).  
2.2 NO functions 
Beside its role as vasodilator various other activities of NO have been described: (I) NO 
preve nts  the  express io n  o f  ce l l  adhes io n  mo lecules  t he reby  prev ent ing 
leukocytes/monocytes adhering to vascular endothelium and their immigration into the  
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Table 1. Basal blood/plasma levels and half-lifes of some NO-related compounds. Values 
are approximated from studies in human. For Hb-NO, S-nitroso-Hb and S-nitroso-albumin, 
no firm agreement about normal values has been reached, and reported values vary greatly. 
T1/2 for Hb-NO is from pig experiments, values for S-nitroso-Hb and S-nitroso-albumin are 
unknown (from J.O. Lundberg and E. Weitzberg, Arterioscler Thromb Vasc Biol, 
2005;25:915-922). 
 
Fig. 1. Nitric oxide signalling axis as therapeutic target in cardiac and vascular disorders. 
The endothelial eNOS catalyses the formation of NO from L-arginine through two 
sequential monooxygenation steps. The nitrogen atom of NO is derived from the 
guanodinogroup of the L-arginine side chain and the oxygen atom of NO derived from 
molecular oxygen. The cGMP generation in the vascular smooth muscle cell is catalysed by 




Nitric Oxide Signalling in Vascular Control and Cardiovascular Risk 
 
281 
arterial wall. The monocytes accumulated in the arterial wall can promote local expression 
or activation of matrixmetalloproteases, which decrease the strength of the cap by degrading 
collagen and other extracellular matrix components. Furthermore, activated macrophages 
kill neighbouring SMC by lytic damage leading to necrosis or by inducing apoptosis (Kockx 
et al., 1996, 1998). (II) NO reduces the influx of lipoproteins into the vascular wall and 
inhibits LDL oxidation. (III) NO inhibits DNA synthesis (Förstermann et al., 1994) and 
proliferation of SMC (Li & Förstermann, 2000; Li et al., 2002a). (IV) NO released towards the 
vascular lumen is a potent inhibitor of platelet aggregation and adhesion (Busse et al., 1987; 
Radomski et al., 1987). (V) NO can react with superoxide anion O2-. forming the potent 
peroxynitrite (ONOO-), which causes oxidative damage, nitration and S-nitrosylation of 
biomolecules. Furthermore, ONOO- oxidizes the NOS cofactor 5,6,7,8-tetrahydrobiopterin 
with the consequence of uncoupling NOS from NO synthesis thereby leading NOS to a 
superoxide producing proarteriosclerotic enzyme (Förstermann, 2006). (VI) Exogenous NO 
released from DETA/NONOate causes overexpression of TGF-beta and extracellular matrix 
in cultured human coronary smooth muscle cells (A. Schmidt et al., 2003).  
2.3 eNOS-independent sources of NO 
The generation of NO is not restricted to NO-synthases. An endothelium-independent 
source of bioactive NO is the ingestion of dietary (inorganic) nitrate. Naturally occurring 
dietary nitrate (celery, cress, chervil, beetroot, spinach, rucula contain up to 250 mg NO/100 
g fresh weight) elevate the tissue und blood plasma level of nitrite via bioconversion in the 
entero-salivary circulation. When nitrite is acidified, it yields HNO2, which decomposes to 
NO and other nitrogen oxides 
  NO2- + H+    HNO2 (1) 
  2 HNO2    N2O2 + H2O (2) 
  N2O2   NO + NO2 (3) 
Studies have indicated that acid-catalysed nitrite reduction to NO can also take place in 
blood vessels and tissues already at a moderately low pH and within nitrite concentrations 
normally present in vivo. 
The NO generated by eNOS has a half-life (T1/2) of 1-2 milliseconds and rapidly oxidizes to 
nitrate (NO2-). Nitrate however is not a final end product of NO metabolism but can be a 
substrate for NOS-independent regeneration to NO (Benjamin et al., 1994; Lundberg et al., 
1994). Therefore other sources of nitrate in mammalians can contribute to the formation of NO 
such as nitrate generated from commensal bacteria in the digestive tract or nitrate present in 
foodstuff. Thus, in a study of Milkowski (Milkowski et al., 2010) it was shown that the 
consumption of nitrite- and nitrate-rich food such as fruits, leafy vegetables, and cured meals 
along with antioxidants can compensate for any disturbance in endogenous NO. Regular 
intake of nitrate-containing food such as green leafy vegetables may ensure that blood and 
tissue levels of nitrite and NO pools are maintained at a level sufficient to compensate for any 
disturbances in endogenous NO synthesis. In several studies (Kapil et al., 2010a, 2010b; Tang 
et al., 2011) it was shown that nitrate supplementation or vegetable intake (such as beetroot 
juice) causes dose-dependent elevation in plasma nitrite concentration, elevation of cGMP 
concentration with a consequent decrease in blood pressure and reduction the risk of 
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ischaemic stroke. The collective body of evidence suggests that food enriched with nitrate and 
nitrite provide significant health benefits with very little risk. The weak and inconclusive data 
on the cancer risk of nitrite/nitrate and processed meats are far outweighed by the health 
benefit of restoring NO homeostasis via dietary nitrite and nitrate (Tang et al., 2011). 
3. Regulation of eNOS activity 
3.1 Phosphorylation 
eNOS synthesizes NO in a pulsatile Ca2+/calmodulin-dependent manner with eNOS activity 
markedly increasing when intracellular Ca2+ increases. Ca2+ induces the binding of calmodulin 
to the enzyme thus increasing the rate of electron transfer from NADPH to heme center 
(Hemmens & Mayer, 1998). However, eNOS can be activated by other stimuli as increased 
intracellular Ca2+. The best-established stimulus is the shear stress of flowing blood, which can 
increase enzyme activity. This activation is mediated by phosphorylation of the enzyme (Fig. 
2). The eNOS protein can be phosphorylated on several Ser, Thr and Tyr residues. Two main 
changes in enzyme function have been found. Phosphorylation of Ser1177 stimulates the flux of 
electrons within the reductase domain and increases the Ca2+ sensitivity of the enzyme 
(Fleming & Busse, 2003). Several protein kinases participate in phosphorylation of eNOS at 
Ser1177. These kinases include Akt, protein kinase A, 5’-AMP activated protein kinase and 
calmodulin-dependent kinase II. A negative regulatory site for phosphorylation is Thr495 under 
non-stimulated conditions probably by protein kinase C. Thr495 interferes with the binding of 
calmodulin to the calmodulin-binding domain. Dephosphorylation of Thr495 is associated with 
stimuli such as histamine and bradykinine both elevating intracellular Ca2+ concentration. 
Dephosphorylation of Thr495 has also been shown to favour eNOS uncoupling (Lin et al., 2003). 
Other phosphorylation sites including Ser114, Ser633 and some Tyr residues are not known to 
have major consequences for enzyme activity (Fleming & Busse, 2003; Fleming, 2010). 
eNOS-associated proteins such as caveolin, heat shock protein 90 or eNOS interacting 
proteins provide the scaffold for the formation of the eNOS protein complex and its 
intracellular location (Fleming & Busse, 2003). 
eNOS levels in endothelial cells can be regulated by changes in eNOS mRNA stability. 
3.2 Enhancers of NO availability 
Statins. Statins are a group of compounds which lower LDL-cholesterol, are inhibiting the 
enzyme 3-hydroxy-3-methylglutaryl coenzyme A. Beside their lipid lowering property 
statins improve vascular relaxation, reduce vascular inflammation, reduce oxidative stress, 
decrease thrombosis and platelet aggregation (E. Schulz et al., 2004; Sowers, 2003). These 
beneficial effects of statins are in part mediated by an effect on eNOS because they can be 
blocked by L-NMMA (L-NG-monomethylarginine), an inhibitor of eNOS (John, et al., 1998; 
Rosenson & Tangney, 1998). Statins increase the expression of eNOS via Rho isoprenylation 
(Laufs et al., 1998) or posttranslational mechanism (Kureishi et al., 2000).  
Superoxide dismutase (SOD). Superoxide dismutase has a key antioxidant role by 
dismutation of O2-. into oxygen and hydrogen peroxide. In humans, three forms of the enzyme 
are present (SOD1, SOD2 and SOD3). In the cardiovascular system, the action of  extracellular 
SOD3 (Cu–Zn–SOD) lowers O2-. and maintains vascular NO levels (Jung et al., 2007).  
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Fig. 2. Regulation of eNOS activity by intracellular Ca2+ and phosphorylation. An increase in 
intracellular Ca2+ (as produced by agonists such as histamine or bradykinin) leads to an 
enhanced binding of CaM (calmodulin) to the enzyme, which in turn displaces an auto-
inhibitory loop and facilitates the flow of electrons from NADPH in the reductase domain to 
the heme in the oxygenase domain. There are several potential phosphorylation sites in 
eNOS, but most is known about the functional consequences of phosphorylation of Ser1177 
(human eNOS sequence) in the reductase domain and Thr495 (human eNOS sequence) 
within the CaM-binding domain. In resting endothelial cells, Ser1177 is usually not 
phosphorylated. Phosphorylation is induced when the cells are exposed to fluid shear stress, 
estrogens, VEGF, insulin, or bradykinin. The kinases responsible for phosphorylation 
depend on the primary stimulus. Shear stress elicits the phosphorylation of Ser1177 by 
activating protein kinase A (PKA), estrogen and VEGF phosphorylate eNOS mainly via Akt, 
insulin probably activates both Akt and the AMP-activated protein kinase (AMPK), and the 
bradykinin-induced phosphorylation of Ser1177 is mediated by CaMKII. Phosphorylation of 
the Ser1177 residue increases the flux of electrons through the reductase domain and thus 
enzyme activity. The Thr495 residue of human eNOS tends to be constitutively 
phosphorylated in endothelial cells. Thr495 is a negative regulatory site, and its 
phosphorylation is associated with a decrease in enzyme activity. The constitutively active 
kinase that phosphorylates eNOS Thr495 is most probably protein kinase C (PKC). The 
phosphatase that dephosphorylates Thr495 appears to be protein phosphatase1. (Figure and 
legend from U. Förstermann, Pflügers Arch - Eur J Physiol, 2010;459:923-933) 
Catalase. Catalase decomposes hydrogen peroxide to water and oxygen. Overexpression of 
catalase has protective effects in the cardiovascular system such as delayed development of 
arteriosclerosis (Yang et al., 2004) and inhibition of angiotensin II-induced aortic wall 
hypertrophy (Zhang et al., 2005). 
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Glutathion peroxidase (GPx). Several isoenzymes of GPx were found in mammals, the 
isoenzyme 1 being most abundant. In patients with coronary artery disease the activity of 
red blood cell GPx1 is inversely associated with the risk of cardiovascular events 
(Blankenberg et al., 2003). In ApoE-deficient mice, the deficiency of GPx1 leads to 
arteriosclerotic lesion progression (Torzewski et al., 2007).  
Heme oxygenase (HO). In break down of heme CO, biliverdin and free ferrous iron are 
formed. The biliverdin is converted to bilirubin, which has radical-scavenging properties 
(Jiang et al., 2006). The carbon monoxide has antiproliferative and anti-inflammatory as well 
as vasodilatory properties (Morita, 2005). 
Thioredoxin (Trx). Thioredoxin seems to exert most of its ROS-scavenging properties 
through Trx peroxidase (peroxiredoxin), which uses endogenous SH groups as reducing 
equivalents. Thioredoxin is present in endothelial- and vascular smooth muscle cells. It 
exerts its ROS-scavenging properties through Trx peroxidase. Trx scavens ROS and nitric 
peroxide, ONOO- (Yamawaki et al., 2003). 
Paraoxonase (PON). The PON family of enzymes acts as vascular antioxidant defense and 
protects against coronary artery disease (Aviram et al., 1998). The PON1 and PON3 enzymes 
are synthesized in the liver and circulate in plasma associated with the high-density 
lipoprotein (HDL) fraction. The capacity of HDL in decreasing HDL and LDL lipid 
peroxidation largely depends on its PON1 content (Aviram et al., 1998). Deletion of the 
PON1 gene increases oxidative stress in mouse macrophages and aortae (Rozenberg et al., 
2005). The enzyme has been shown to reduce ROS in human endothelial cells, vascular 
smooth muscle cells, and fibroblasts (Horke et al., 2007). 
4. eNOS – A multiple cofactors-dependent enzyme 
eNOS is a homodimer protein and consists of two subunits: (I) the alpha reductase domain 
which is able to transfer electrons from NADPH to FAD and FMN and can bind calmodulin 
for stimulation of electron transfer. It has a limited capacity to reduce molecular oxygen to 
superoxide (O2-.) (Stuehr et al., 2001). (II) The oxygenase domain of eNOS is unable to bind 
the cofactor 5,6,7,8-tetrahydrobiopterin or L-arginine and can not catalyse NO production. 
The presence of heme allows for NOS dimerization and is the only cofactor that is essential 
for NOS for the interaction and coupling reductase and oxygenase domains. eNOS 
monomers are unable to bind the 5,6,7,8-tetrahydrobiopterin or the L-arginine and can not 
catalyse NO production. Under pathological conditions the molecular oxygen is no longer 
coupled to L-arginine reduction but results in the production of superoxide. This 
phenomenon is referred to eNOS uncoupling (Förstermann & Münzel, 2006; Li et al., 2002b). 
5. eNOS uncoupling 
5.1 Molecular mechanisms leading to eNOS uncoupling  
Various mechanisms can contribute to eNOS uncoupling (Fig. 3). Their inbalance causes 
eNOS dysfunction and cardiovascular risk. This has been shown by numerous clinical 
studies and for experimental animals. (I) Inhibition of eNOS activity. A lack or deficiency of 
eNOS disrupted at the calmodulin binding site resulted in enhanced arteriosclerosis or 
peripheral coronary arteriosclerosis and aortic aneurism in ApoE/eNOS double knock out 
mice (Chen et al., 2001; Hodgin et al., 2002; Knowles et al., 2000; Kuhlencordt et al., 2001). 
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(II) eNOS uncoupling factors such as hypercholesterolemia, diabetes, smoking, 
hypertension are associated with endothelial dysfunction. Evidence for uncoupling of eNOS 
has been obtained in endothelial cells treated with LDL (Pritchard et al., 1995) in 
peroxynitrite-treated rat aorta (Laursen et al., 2001) and in spontaneously hypertensive rats 
(Li et al., 2006), in human diabetes (Heitzer et al., 2000) and streptozotocin-induced diabetic 
rats (Hink et al., 2001). (III) Arginine deficiency. L-arginine – the physiological substrate of 
eNOS – is a constituent amino acid and present in human blood plasma in a concentration 
of 113.6±14.6 µM (Psychogios et al., 2011). A decrease of L-arginine induced in 
hypercholesterolemia below physiological levels favours eNOS uncoupling and formation 




Fig. 3. Scheme of an endothelial NO synthase (eNOS) whose oxygen reduction is uncoupled 
from NO synthesis. Oxidative stress is associated with endothelial dysfunction. ONOO− can 
oxidize BH4 to biologically inactive products such as trihydrobiopterin radical (BH3·) or 
trihydrobiopterin radical cation protonated at N5 (BH3·H+). The BH3· radical can be 
converted to the quinonoid 6,7-[8H]-H2-biopterin (BH2), which also lacks biological activity. 
When ONOO− overwhelms the cell’s capacity to re-reduce these products to BH4, eNOS 
“uncouples” and reduces oxygen to O2−·, but does not synthesize NO anymore. eNOS then  
contributes to oxidative stress in the cell. (Figure and legend from U. Förstermann, Pflügers 
Arch - Eur J Physiol, 2010;459:923-933) 
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component of blood plasma in a concentration of 0.4-0.8 µM (Billecke et al., 2009) and acts as 
an endogenous inhibitor of eNOS. ADMA is formed by dimethylation of protein-bound L-
arginine and released by proteolysis. ADMA acts as a local competitor of L-arginine (Cooke, 
2004; Maas, 2005). Arginase is an ubiquitous enzyme which catalyses the degradation of 
arginine to ornithine and urea. Two isoenzymes are found in mammals. Arginase I catalyses 
the final step of the urea cycle in liver. Arginase II is a mitochondrial enzyme that functions 
in L-arginine homeostasis and can be dysregulated by ox LDL (Ryoo et al., 2006) resulting in 
eNOS uncoupling. (IV) 5,6,7,8-tetrahydrobiopterin deficiency. 5,6,7,8-tetrahydrobiopterin 
deficiency causes eNOS dysfunction and uncoupling (Moens & Kass, 2006), if the primary 
function of 5,6,7,8-tetrahydrobiopterin such as both allosteric and redox function, the 
improvement, the binding affinity of L-arginine for eNOS and providing the second electron 
to the heme of eNOS are missing. These alterations have the consequence that the reduction 
of molecular oxygen still occurs at the heme site of eNOS but oxidation of the guanidine 
nitrogen of L-arginine is prevented so that the reduced oxygen is converted by the 
uncoupled eNOS to superoxide instead of NO and citrulline (Gao et al., 2007; Xia et al. 
1998). Even the partially oxidized 5,6,7,8-tetrahydrobiopterin - the 7,8-tetrahydrobiopterin 
(BH2) - has no eNOS cofactor activity and is unable to prevent superoxide formation of 
eNOS (Gao et al., 2007). In addition, BH2 probably competes with BH4 for eNOS binding. 
Therefore the ratio BH4/BH2 is important for eNOS activity (Shinozaki et al., 1999; Vasquez-
Vivar et al., 2002). Apparently a diminished BH4/BH2 level rather than BH4 deficiency is a 
molecular trigger for eNOS uncoupling (Crabtree et al., 2008). Normally the majority of BH4 
is present in vascular endothelial cells (Antoniades et al., 2007; Katusic, 2001) in a 
concentration of 1.40 pM/106 cells. Intracellular BH4 concentration has been found under 
hypercholesterolemic conditions thus aortic BH4 levels are decreased by 50% in 
hypercholesterolemic ApoE knockout mice compared with wild-type mice (Ozaki et al., 
2002), but also discrepant results are described (d'Uscio et al. 2003; d'Uscio & Katusic, 2006) 
apparently depending on the degree of hypercholesterolemia and differences in the level of 
oxidative stress. The tissue level of BH4 is determined by the balance of biosynthesis from 
GTP via de novo synthesis by GTP cyclo hydrolase (GCH-1) or by the salvage pathway from 
BH2 back to BH4 and degradation by oxidation of BH4 to BH2 (T.S. Schmidt & Alp, 2007) – a 
process that can be rapidly accelerated by peroxynitrite (Landmesser et al., 2003; Laursen et 
al., 2001; Zou et al. 2002). 
The oxidase-mediated stress of BH4 can be increased by several ROS producing enzyme 
systems such as NADPH oxidase that plays a major role in vascular cells (Förstermann, 
2008; Harrison et al., 2003; Schnabel & Blankenberg, 2007), by xanthine oxidase, cytochrome 
P450 monooxygenase and enzymes of the respiratory chain. Xanthine oxidase is generated 
from xanthine dehydrogenase by proteolysis. This enzyme is another potential source of 
ROS in vascular disease. The enzyme readily donates electrons to molecular oxygen, thereby 
producing O2-. and hydrogen peroxide. Oxypurinol, an inhibitor of xanthine oxidase 
decreases O2-. production and improves endothelium-dependent vascular relaxation to 
acetylcholine in blood vessels from hyperlipidemic animals (Ohara et al., 1993). This 
suggests a contribution of xanthine oxidase to endothelial dysfunction in early 
hypercholesterolemia. Experimental evidence suggests that endothelial cells themselves can 
express xanthine dehydrogenase (xanthine oxidase) and that this expression is regulated in 
a redox sensitive way depending on endothelial NADPH oxidase (McNally et al., 2003). 
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All these cited cofactors required for regulation eNOS activity depend on the physiological 
transcription and translation of the corresponding genes. These processes, however, are 
regulated by epigenetics. Epigentics refer to chromatin-based pathways including three 
distinct but highly interrelated mechanisms: DNA methylation, Histone density and 
posttranslational modifications. These factors together offer new perspectives on 
transcriptional control paradigm in vascular endothelial cells and provide a molecular basis 
for understanding how the environment impacts the genome to modified function and 
disease susceptibility (Yan et al., 2010). 
5.2 Mechanisms leading to a loss of function of eNOS 
Oxidative stress is associated with endothelial dysfunction. Mechanistically, superoxide 
derived from NADPH oxidases and/or xanthine oxidase may combine with NO formed by 
a still functional eNOS. This would lead to increased formation of peroxinitrite (Laursen et 
al., 2001). Peroxynitrite has been shown to oxidize BH4 to biological inactive products. 
Significant O2-. production also occurs when concentrations of L-arginine fall below the 
levels required to saturate the enzyme. In these circumstances eNOS catalysis the uncoupled 
reduction to O2 leading to the production of O2-. and/or H2O2. Whether L-arginine 
concentration ever becomes critical as a substrate in vivo appears questionable since the Km 
of eNOS for L-arginine is ~3 µM while the L-arginine plasma concentration is ~100 µM and 
a ~10-fold accumulation of L-arginine within cells (Closs et al., 2000). 
5.3 eNOS uncoupling in arteriosclerosis 
Under cardiovascular risk factors such as diabetes, hypertension, smoking, the enzymatic 
reduction of molecular oxygen by eNOS is no longer used for L-arginine conversion to 
citrulline and NO, but the uncoupling of oxidase and reductase chain of eNOS produced ROS 
via the NADPH domains. The cardiovascular risk factors initiate the eNOS uncoupling and 
this can occur before arteriosclerotic lesions can be detected. The eNOS uncoupling can be 
triggered by various mechanisms which include BH4 deficiency, shortage of L-arginine or HSP 
90, inhibitory phosphorylation of eNOS on Thr495 (see above) eNOS redistribution to the 
cytosolic fraction of the cell, oxidation of the zinc-thiolate cluster in eNOS or elevated ADMA 
levels (Sud et al. 2008). Among all of these mechanisms the reaction BH4 to BH2 is probably a 
dominant factor, and BH4 deficiency seems to be the primary cause for eNOS uncoupling in 
pathophysiology. Some researchers have postulated that eNOS may exist in two separate 
pools: a coupled form and an uncoupled form. The coupled enzyme is associated with the 
membrane and is readily accessible to the "signalome" for activation and NO production, 
whereas the uncoupled enzyme may reside in the cytosol and produces superoxide (Gharavi 
et al., 2006; Sullivan et al., 2006). In eNOS overexpressing mice for example, there is clear 
evidence for eNOS uncoupling (i.e. eNOS-mediated ROS production). In the same mice, 
however, NO-generating activity is elevated 2-fold when compared with wild-type mice (the 
total eNOS protein levels are elevated 8-fold) (Bendall et al., 2005). Thus, it is possible that 
coupled eNOS and uncoupled eNOS may exist in the same tissue at the same time. 
The principle mechanisms of vascular protection by eNOS-derived NO and the 








Table 2. The vaso-protective effect of eNOS is not restricted to the control of arterial dilation 
and constriction. The NO released towards the vascular lumen is a potent inhibitor of 
platelet aggregation and adhesion. The expression and formation of the alpha and beta 
component of various integrins including the cell adhesion molecules ICAM and VCAM can 
also be inhibited and reduce the transendothelial migration of macrophages and T-
lymphocytes known to be an early event in the development of arteriosclerosis and 
characteristic for its inflammatory phases. The uncoupled eNOS leads to an excessive 
production of superoxide (O2-. ) and in turn to the formation of highly toxic peroxynitrite 
(Förstermann & Münzel, 2006). 
6. eNOS-independent production of reactive oxygen species in vascular 
disease 
Beside the eNOS there are several enzymes that can produce ROS in the endothelial cells: 
NADPH oxidase, xanthine oxidase, and enzymes of the mitochondrial respiratory chain are 
of major importance. 
NADPH oxidases. Several isoforms of ROS producing NADPH oxidase are present and 
active in the vascular wall. In arteriosclerotic arteries the NADPH oxidase subunits NOX 2 
and NOX 4 (Sorescu et al., 2002) have been identified. 
Xanthine oxidase (XO). Increased cholesterol levels have been shown to stimulate the 
release of xanthine oxidase from the liver into the circulation. The circulating xanthine 
oxidase than can associate with endothelial glycosaminoglycans (White et al., 1996) 
however endothelial cells themselves can express xanthine oxidase and the expression is 
regulated in a redox sensitive pathway depending on endothelial NADPH oxidase 
(McNally et al., 2003) (Fig. 4). 
Respiratory chain of the mitochondria. The molecular oxygen is consumed by 
mitochondria thereby forming O2-.. Evidence has been provided that some cardiovascular 
diseases are associated with mitochondrial dysfunction (Ramachandran et al., 2002) and the 








Fig. 4. XO and NOS are capable of generating either NO or superoxide (O2) depending on 
the conditions. When the supply of L-arginine and oxygen is good, NOS makes NO, 
whereas the same enzyme may generate considerable amounts of superoxide when L-
arginine or cofactors are limited. XO generates superoxide, for example, during reperfusion 
after ischemia, whereas nitrite reduction to NO occurs preferentially during hypoxia. NO 
generation from XO can be beneficial and works as a backup system to supply NO during 
hypoxia when NO synthesis from NOS is compromised. Detrimental effects of these 2 
enzyme systems can also be foreseen, for example, in a situation in which NO and 
superoxide are generated simultaneously and react to form potentially harmful 
peroxynitrite. (Figure and legend from J.O. Lundberg and E. Weitzberg, Arterioscler 
Thromb Vasc Biol, 2005;25:915 – 922) 
7. Factors protecting against eNOS uncoupling and oxidative stress 
7.1 Nitric oxide donors 
NO-delivering drugs (NO donors) are used for their potential therapeutic benefit in 
coronary heart disease risk patients (D.J. Lefer & A.M. Lefer, 1988) by increasing coronary 
blood flow and dilating coronary arteries. Several studies have described the action of NO 
donors on vascular smooth muscle cells (Sarkar et al., 1997; A. Schmidt et al. 2003; Young et 
al., 2000). The pathway leading to NO formation differs among individual NO donor 
classes: indirect NO donors such as organic nitrates (nitroglycerol, isosorbide mononitrate, 
isosorbide dinitrate) require enzymatic catalysis, other NO donors require interaction with 
thiols to release NO, some have to undergo oxidation or reduction. In contrast, direct NO 
donors generate NO non-enzymatically. Examples are nicorandil, SIN-1 (the active 
metabolite of molsidomine) and the group of 1-substituted diazen-1-ium-1,2-diolates that 
releases NO spontaneously with a half-life from minutes to hours (Mooradian  et al., 1995).  
7.2 The NO donor DETA/NONOate 
The compound (Z)-1-[2-Aminoethyl)–N–(2-ammonioethyl) amino] diazen-1-ium-1,2-diolate 
(in the following detNO) belongs to the class of direct NO donors. Under cell culture 
conditions detNO releases spontaneously NO with a half-life of about 20 h at 37° C in a strictly 
first order reaction (Hrabie et al., 1993; Keefer et al., 1996; Mooradian et al., 1995), thereby 
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disintegrating to two NO and diethylentriamine. Diethylentriamine, the byproduct of detNO 
disintegration, is known to be effectiveless (Mooradian et al., 1995; Sarkar et al., 1997). detNO 
has been successful used (Boyle et al., 2002; Ishimaru et al., 2001; A. Schmidt  et al., 2003). In 
experimental studies (A. Schmidt et al., 2008) on cultured endothelial cells exogenously 
applied NO released from the NO donor detNO has a dual function in the regulation of eNOS 
expression. During short–term exposure of endothelial cells, exogenous detNO enhances the 
phosphorylation of the protein kinase Akt that in turn activates eNOS of endothelial cells by 
increasing its phosphorylation leading to a higher release of endogenous NO. 
Phosphorylation can be achieved by exposure of human vascular endothelial cells to 150 
µmol/L detNO. In short-term experiments in Western blot analysis detNO shows a clear 
increase of eNOS phosphorylation at Ser1177 after a short lag phase, detectable 20 min after 
detNO addition. The phosphorylation is mediated by the protein kinase Akt that is 
converted into p-Akt within 10 min after addition of detNO in a concentration-dependent 
manner. The phosphorylated Akt increases in turn Ser1177 phosphorylation of eNOS. This 
phosphorylation cascade could be reverted by preincubation of the cells with the PI-3 kinase 
inhibitor LY294002 that prevents phosphorylation of both Akt and eNOS. Thr495 is 
constitutively phosphorylated in all endothelial cells (Fleming & Busse, 2003) and is a 
negative regulatory site, i.e. phosphorylation leads to a decrease of eNOS activity. The 
release of endogenous NO in response to exogenous detNO was confirmed by L-[2,3,4,5-
3H]arginine as indicator. The eNOS-mediated conversion of [3H]arginine to NO and 
[3H]citrulline was measured and the results are given in [3H]citrulline equivalents. A 
statistically significant increase of endogenous NO production after 20 and 30 min exposure 
to detNO is shown. N-nitro-L-arginine methyl ester HCl (NAME), a competitive NOS 
inhibitor, verifies the reaction conditions of the assay. Taking this reaction sequence into 
account, the effect of the NO donor could be considered partially a trigger for the 
acceleration of endogenous NO production that finally effects vasodilation via the 
physiologic pathway. This leads to the hypothesis of a potential switch from an exogenously 
applied to an endogenously generated NO stimulation (Fig. 5). 
7.3 Long-term application of detNO and other NO donors 
In contrast an exposure of endothelial cells to detNO for 24 and 48 h reduces the eNOS 
protein content as compared with controls. Densitometry revealed a reduced eNOS protein 
content after 24 h and 48 h. Real-time RT-PCR confirmed the reduced transcription of eNOS-
specific mRNA. For direct determination of the reduced eNOS enzyme activity after long-
term exposure to detNO, [2,3,4,5-3H]arginine was added to the culture medium. The 
radioactivity of [3H]citrulline formed by the NADPH-dependent NOS oxidoreductase is 
direct proportional to the NO produced and released by the endothelial cells. Under these 
conditions the results show a significant reduction of NO production expressed as 
[3H]citrulline equivalents in accordance to the reduced Ser1177 phosphorylation of eNOS. 
Taken together, these results emphasize a limitation of NO donors as long-term therapeutics 
owing to the inhibition of eNOS synthesis. However, whether exogenous NO donors are 
operative and effective in a similar way also in humans is still uncertain. In numerous 
clinical studies the outcome of repeated administration of indirect or direct NO donors to 
patients with coronary artery disease were ambiguous and the potential benefit of long-
acting nitrates has remained controversial. Pathways leading to NO formation differ 
significantly among individual NO donor classes. In the Fourth International Study of  
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Fig. 5. Scheme of the new mechanism of action of the NO-donor DETA/NONOate in 
cultured human vascular endothelial cells. During short-term exposure the exogenous NO 
donor enhances the phosphorylation of the protein kinase Akt (PKB) that in turn activates 
eNOS of the endothelial cells by increasing its phosphorylation of Ser1177 leading to a higher 
release of the physiological endogenous NO as judged by the conversion of [3H]arginine  to 
[3H]citrulline. The NOS-released NO reaches the smooth muscle cell and effects 
vasodilation.  
Infarct Survival (ISIS-4), there was no significant reduction in five-week mortality and no 
survival advantage (ISIS-4 (Fourth International Study of Infarct Survival) Collaborative 
Group, 1995). Chronic administration of long acting nitrates in patients with healed 
myocardial infarction resulted in an increased number of patients with cardiac events 
(Ishikawa et al., 1996) and an increased risk of cardiac deaths occurred in CAD patients with 
long acting nitrates (Nakamura et al., 1999). Furthermore, a study on 19 healthy volunteers 
documented that isosorbide mononitrate given over 7 days impaired endothelial function 
due to formation of free radicals (Thomas et al., 2007). In total, epidemiological evidence 
indicates that chronic administration of long acting nitrates increase rather than decreases 
fatal and non-fatal events (Ishikawa et al., 1996; Nakamura et al., 1999). This view is 
confirmed by experiments on human vascular endothelial cells, which show detNO-induced 
cell cycle arrest and hypertrophy. Cultured quiescent EC released from the Go-phase by 
seeding at a low density re-enter the cell cycle and proliferate up to confluence. In this phase 
detNO causes a dose-dependent suppression of proliferation of EC indicated by a decreased 
incorporation of [3H]thymidine and a cell cycle arrest. The antiproliferative effect of detNO 
was associated with a remarkable increase of cell protein content that continued up to a 2-3-
fold amount of control cells within 3 days while the cell number indicates an inhibition of 
cell proliferation and shows neither increase nor decrease. The elevated total cell protein 
was the result of de novo synthesis indicated by measurements of [3H]leucine incorporation 
into total cellular protein. After 48 h incubation of subconfluent cultures in the presence of 
[4,5-3H]leucine the incorporated radioactivity was 24.8 x 103 dpm/105 control cells and 34.6 
x 103  dpm/105 cells exposed to detNO. The concomitant upregulation of p21 refers to a 
block at the G1-phase of the cell cycle. The detNO-induced metabolic alterations convert the 
cells into a hypertrophic phenotype.  Measurements of cell volume show an increase from 
2.49  0.18 up to 3.38  0.36 (200 µmol/L detNO) fL /cell.  
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The inhibition of proliferation is cytostatic but not cytotoxic as evaluated by cell death 
determination and is reversible. A quantitative determination of mono- and 
oligonucleosomes revealed no significant apoptotic cell death in detNO-pretreated cells. 
When the medium of detNO-induced growth-arrested cells is replaced by a standard 
medium, cell proliferation recovers within the following 48 h with continuous increase of 
cell number. 
7.4 Antioxidant compounds potentially protecting against vascular oxidative stress 
Important antioxidant enzymes include superoxide dismutase (SOD), glutathione 
peroxidase (GPx), catalase, heme oxygenase (HO), and the thioredoxin (Trx) peroxidase and 
perhaps also paraoxonases (PON) (see Chapter 3.2). 
Pentaerythritol tetranitrate (PETN) is a NO donor that does not induce significant nitrate 
tolerance and reduces oxidative stress (probably by inducing heme oxygenase).  Sepiapterin 
can be reduced in cells by sepiapterin reductase (SR) to 7,8-BH2, sepiapterin reductase 
catalyses the following reaction 
7,8-dihydrobiopterin + NADP+     tetrahydrobiopterin + NADPH + H+ 
Midostaurin, betulinic acid and ursolic acid upregulate eNOS and concomitantly decrease 
NADPH oxidase expression (Li & Förstermann, 2009).  
AVE9488 and AVE3085, a new class of eNOS enhancers, upregulated the promotor activity 
of eNOS in vitro and in vivo. Application to wild type and ApoE-knockout mice over 12 
weeks enhanced vascular eNOS expression at mRNA and protein level (Xue et al., 2010). 
The hybrid NO-releasing prodrug PABA/NO can be stabilized as nanoparticle with 
significant stability in mice circulation over 24h (Kumar et al., 2010).   
Nebivolol - a NO-releasing beta-blocker induced a consistent increase of aortic eNOS 
expression rabbits receiving high-cholesterol diet (de Nigris et al., 2008). NO-releasing S-
nitrosothiol-modified xerogels are capable of generating NO for up to 2 weeks (Riccio et al., 
2009). These new generation of NO donors might be a rational approach to develop a new 
generation of antiatherogenic and anti-inflammatory NO donors. AVE9488 and AVE3085 
are eNOS transcription enhancers that reverse eNOS uncoupling and preserve eNOS 
functionality.  
Angiotensin II type 1-receptor blockers (ARBs), estrogens and erythropoietin (EPO) 
enhance (6R)-5,6,7,8-BH4 synthesis by stimulating GCH1 expression or activity (Li & 
Förstermann, 2009.) 
Angiotensin-converting enzyme (ACE) inhibitors, the aldosterone antagonist eplerenone 
and the renin inhibitor aliskiren prevent (6R)-5,6,7,8-BH4 oxidation by decreasing the 
expression and/or activity of NADPH oxidase. 
8. Clinical implications 
Cardiovascular risk factors cause oxidative stress that alters the endothelial cells capacity 
and leads to endothelial dysfunction. The term „endothelial dysfunction“ is used to refer to 
an incompetence of endothelial cell-dependent vasorelaxation resulting from eNOS 
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uncoupling but a molecular or biochemical basis for biomarkers indicating uncoupled eNOS 
has not been established. A biomarker is a characteristic that is objectively measured and 
evaluated as an indicator for normal or pathogenic processes or pharmacological response 
to a therapeutic intervention. As biomarkers for cardiovascular diseases oxLDL, CRP, IL-6, 
fibrinogen, TNF-alpha, MMP-9, MPO and cell adhesion molecules have been proposed 
(Vasan, 2006). Indirect biomarkers for eNOS uncoupling are a number of pharmaceuticals 
that have been shown to act as vaso-protective agents. Such agents listed by Förstermann 
(Förstermann, 2010) are: pentaerythritol tetranitrate, a NO donor that does not induce 
significant nitrate tolerance and reduces oxidative stress probably by inducing heme 
oxygenase 1, L-arginine stimulates NO release from eNOS, folic acid may improve eNOS 
functionality by stabilising BH4 and stimulating the endogenous regeneration of BH2 back to 
BH4, sepiapterin can be reduced in cells by sepiapterin reductase to BH2 and further 
dihydrofolate reductase to form BH4, midostaurin, betulinic acid and ursolic acid upregulate 
eNOS and concomitantly decrease NADPH oxidase expression, AVE9488 and AVE3085 are 
eNOS transcription enhancers that reverse eNOS uncoupling and preserve eNOS 
functionality, statins, angiotensin II type 1-receptor blockers, estrogens and erythropoietin 
enhance BH4 synthesis by stimulating GTP cyclohydrolase1 expression or activities. Statins, 
angiotensin converting enzyme inhibitors, the aldosterone antagonist eplerenone and the 
renin inhibitor prevent BH4 oxidation by decreasing the expression and/or activity of 
NADPH oxidase. All these compounds are secondary biomarkers indicating a 
pharmacological response to a therapeutic intervention.  
Clinically, endothelial function can be assessed by invasive or non-invasive techniques (for 
review see Esper et al., 2006). These techniques evaluate the endothelial functional capacity 
depending on the amount of NO produced and the resulting vasodilation effect. The 
percentage of vasodilation with respect to the basal value represents the endothelial functional 
capacity. A non-invasive technique most often used is the transient flow-modulate 
endothelium-dependent post-ischemic vasodilation performed on conductance arteries such 
as the brachial, radial or femoral arteries. This vasodilation is compared with the vasodilation 
produced by NO donors. The vasodilation is quantified by measuring the arterial diameter 
with high-resolution ultrasonography. Laser-Doppler techniques are used to consider tissue 
perfusion. There is no doubt that endothelial dysfunction contributes to the initiation and 
progression of arteriosclerosis and could be considered an independent vascular risk factor. 
9. Conclusion  
Nitric oxide produced in vascular endothelial cells by the nitric oxide synthase is a major 
signalling molecule for maintaining vascular homeostasis. The nitric oxide synthase  - 
constitutionally expressed by endothelial cells – is a dimeric enzyme molecule depending on 
multiple cofactors for its physiological activity and optimal endothelial function. Any 
imbalance of reductase and NADPH oxygenase or deficient supply of the enzyme substrate 
L-arginine or of cofactors leads to an upregulation of endothelial nitric oxide synthase and 
oxygenase activity with the consequence of an uncoupling of the nitric oxide synthase and 
production of detrimental reactive oxygen species and/or highly toxic peroxinitrate instead 
of nitric oxide. The resulting endothelial dysfunction implies a high cardiovascular risk. 
Several drugs reverting endothelial nitric oxide synthase uncoupling and/or improving 
endothelial dysfunction are in clinical use. Nitric oxide delivering drugs (NO donors) show 
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potential therapeutical benefit and are used to relief or prevent acute episodes of angina 
pectoris by activating the endothelial nitric oxide synthase – a new mechanism found for the 
NO donor DETA/NONOate. However, a long-term administration of NO donors has been 
found to reduce endothelial nitric oxide synthase of endothelial cells drastically (in cell 
culture experiments). This could be the basis for development of a new generation of NO 
donors that mimics the low continuous pulsatile stress-induced release of endogenous nitric 
oxide. 
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